MCID: OVR096
MIFTS: 28

Overlap Myositis

Categories: Bone diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Overlap Myositis

MalaCards integrated aliases for Overlap Myositis:

Name: Overlap Myositis 59
Adult-Onset Overlap Myositis 59
Non-Specific Myositis 59
Myositis 72

Characteristics:

Orphanet epidemiological data:

59
overlap myositis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA206572
UMLS 72 C0027121

Summaries for Overlap Myositis

MalaCards based summary : Overlap Myositis, also known as adult-onset overlap myositis, is related to juvenile overlap myositis and myositis, and has symptoms including muscle weakness, myoclonus and myalgia. The drugs Oseltamivir and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and liver.

Related Diseases for Overlap Myositis

Diseases in the Overlap Myositis family:

Juvenile Overlap Myositis

Diseases related to Overlap Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 23)
# Related Disease Score Top Affiliating Genes
1 juvenile overlap myositis 12.6
2 myositis 10.3
3 connective tissue disease 10.1
4 polymyositis 10.1
5 dermatomyositis 10.1
6 myopathy 10.1
7 scleroderma, familial progressive 10.0
8 inclusion body myositis 9.9
9 idiopathic inflammatory myopathy 9.9
10 raynaud phenomenon 9.9
11 parkinson disease, late-onset 9.8
12 systemic lupus erythematosus 5 9.8
13 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
14 exanthem 9.8
15 muscular disease 9.8
16 pericarditis 9.8
17 calcinosis 9.8
18 interstitial lung disease 9.8
19 mixed connective tissue disease 9.8
20 systemic scleroderma 9.8
21 movement disease 9.8
22 tetrasomy 9p 9.8
23 dysphagia 9.8

Graphical network of the top 20 diseases related to Overlap Myositis:



Diseases related to Overlap Myositis

Symptoms & Phenotypes for Overlap Myositis

UMLS symptoms related to Overlap Myositis:


muscle weakness, myoclonus, myalgia, back pain, torticollis, sciatica, muscle cramp, muscle rigidity, muscle spasticity

Drugs & Therapeutics for Overlap Myositis

Drugs for Overlap Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
2
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Ezetimibe Approved Phase 4 163222-33-1 150311
6
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
9
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
10
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
11
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
12 Anti-Infective Agents Phase 4
13 Anti-HIV Agents Phase 4
14 Anti-Retroviral Agents Phase 4
15 Antiviral Agents Phase 4
16 Nucleic Acid Synthesis Inhibitors Phase 4
17 Reverse Transcriptase Inhibitors Phase 4
18 Central Nervous System Depressants Phase 4
19 Folate Phase 4
20 Vitamin B9 Phase 4
21 Vitamin B Complex Phase 4
22 Protective Agents Phase 4
23 Micronutrients Phase 4
24 Trace Elements Phase 4
25 Vitamins Phase 4
26 Nutrients Phase 4
27 Antioxidants Phase 4
28 Ezetimibe, Simvastatin Drug Combination Phase 4
29 Liver Extracts Phase 4
30 Vasodilator Agents Phase 4
31 Vitamin B3 Phase 4
32 Nicotinic Acids Phase 4
33 Lipid Regulating Agents Phase 4
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
35 Hypolipidemic Agents Phase 4
36 Anticholesteremic Agents Phase 4
37 Antimetabolites Phase 4
38
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 6436030 5284616 46835353
39
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
40
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
41
Infliximab Approved Phase 2, Phase 3 170277-31-3
42
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
43
leucovorin Approved Phase 3 58-05-9 143 6006
44
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
45
Lenograstim Approved, Investigational Phase 3 135968-09-1
46
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
47
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
48
Abatacept Approved Phase 3 332348-12-6 10237
49
Sodium citrate Approved, Investigational Phase 3 68-04-2
50
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
3 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
4 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
5 Rho-kinase in Patients With Atherosclerosis: Effects of Statins A Randomized Clinical Trial Comparing Ezetimibe/Simvastatin and Simvastatin Completed NCT00560170 Phase 4 Simvastatin (Zocor);10mg/10mg of Ezetimibe/Simvastatin (Vytorin)
6 The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment Completed NCT03121521 Phase 4 Melatonin 10 mg;Placebo
7 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
8 Double Blind, Prospective Randomized, Crossover Study of Patients With Muscle Complaints on Statin Therapy Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
9 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
10 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
11 Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
12 Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI" Completed NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
13 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
14 An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
15 Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02573467 Phase 3 Bimagrumab;Placebo
16 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
17 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
18 Effect of 80-mg Atorvastatin on Myocardial Edema Following Coronary Artery Bypass Surgery in Relation With Follistatin-Like Protein-1 Completed NCT02901379 Phase 3 Atorvastatin 80mg;Atorvastatin 10mg
19 High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) Completed NCT00501995 Phase 3 IV Cyclophosphamide
20 A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
21 High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage: Is it Better? Completed NCT01077206 Phase 2, Phase 3 Simvastatin
22 Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
23 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
24 A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
25 Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study") Active, not recruiting NCT02728752 Phase 3 Octagam 10%
26 MOVE TRIAL: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT03312634 Phase 3 Palovarotene
27 An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial Enrolling by invitation NCT04049097 Phase 3 Arimoclomol
28 Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical Trial Not yet recruiting NCT03958344 Phase 3 Prednisolone;Triamcinolone + Betamethason
29 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial Not yet recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
30 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
31 A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
32 A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
33 Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
34 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
35 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
36 FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
37 Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors. Completed NCT00519363 Phase 1, Phase 2 atorvastatin
38 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Completed NCT02190747 Phase 2 Palovarotene;Placebo
39 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
40 A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Coadministered With Fenofibrate in Subjects With Combined Hyperlipidemia Completed NCT00813527 Phase 2 Lapaquistat acetate and fenofibrate;Fenofibrate
41 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
42 Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
43 A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
44 Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) Completed NCT00303446 Phase 2 Dutasteride;Placebo
45 A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients Completed NCT00005571 Phase 2 h5G1.1-mAb
46 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
47 A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome Recruiting NCT03215927 Phase 2 Abatacept
48 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
49 A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Recruiting NCT04033926 Phase 2 KZR-616;Placebo
50 STAT (STatins and Aspirin in Trauma) Trial: A Phase II, Pragmatic, Prospective, Randomized, Double-blind, Adaptive Clinical Trial Examining the Efficacy of Statins and Aspirin in the Reduction of Acute Lung Injury and Venous Thromboembolism in Patients With Fibrinolysis Shutdown Recruiting NCT02901067 Phase 2 Aspirin and Rosuvastatin;Placebo (for Aspirin and Rosuvastatin)

Search NIH Clinical Center for Overlap Myositis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carisoprodol
Chlorphenesin
chlorphenesin carbamate
Chlorzoxazone
cyclobenzaprine
Cyclobenzaprine hydrochloride
metaxalone
Methocarbamol
Orphenadrine
Orphenadrine Citrate
Orphenadrine Hydrochloride
tizanidine
tizanidine hydrochloride

Genetic Tests for Overlap Myositis

Anatomical Context for Overlap Myositis

MalaCards organs/tissues related to Overlap Myositis:

41
Lung, Bone, Liver, Kidney, Skeletal Muscle, T Cells, Testes

Publications for Overlap Myositis

Articles related to Overlap Myositis:

(show top 50) (show all 69)
# Title Authors PMID Year
1
Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry. 38
30968571 2019
2
Physical therapy in adult inflammatory myopathy patients: a systematic review. 38
31115788 2019
3
Diagnostic value of additional histopathological fascia examination in idiopathic inflammatory myopathies. 38
31220379 2019
4
18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications. 38
30664602 2019
5
Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. 38
30639643 2019
6
Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. 38
30392161 2019
7
Outcomes of Pregnancy in Women With Inflammatory Myositis: A Retrospective Cohort From India. 38
30720702 2019
8
Juvenile idiopathic inflammatory myopathies: A clinicopathological study with emphasis on muscle histology. 38
30706861 2019
9
Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice. 38
30714969 2019
10
Muscle disease in scleroderma. 38
30148800 2018
11
The clinico-serological spectrum of overlap myositis. 38
30074509 2018
12
Classification and management of adult inflammatory myopathies. 38
30129477 2018
13
Immune checkpoint failures in inflammatory myopathies: An overview. 38
29885538 2018
14
C4d as a marker of complement activation in dermatomyositis muscle tissue. 38
30038095 2018
15
Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. 38
29363513 2018
16
Revisiting Pathological Classification Criteria for Adult Idiopathic Inflammatory Myopathies: In-Depth Analysis of Muscle Biopsies and Correlation Between Pathological Diagnosis and Clinical Manifestations. 38
29522204 2018
17
Current Classification and Management of Inflammatory Myopathies. 38
29865091 2018
18
Prevalence and clinical correlates of rheumatoid factor and anticitrullinated protein antibodies in patients with idiopathic inflammatory myopathy. 38
30116555 2018
19
[Myositis: more than a muscle disease]. 38
29473539 2018
20
Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: Descriptive Analysis. 38
27616211 2017
21
Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. 38
28866745 2017
22
Profile of Pediatric Idiopathic Inflammatory Myopathies from a Tertiary Care Center of Eastern India. 38
28251541 2017
23
Sjögren's syndrome-associated myositis with germinal centre-like structures. 38
27988437 2017
24
[Diagnosis of Idiopathic Inflammatory Myopathy: A Muscle Pathology Perspective]. 38
27916753 2016
25
Myopathy in scleroderma and in other connective tissue diseases. 38
27548651 2016
26
Advances in serological diagnostics of inflammatory myopathies. 38
27538058 2016
27
Whole-body MRI for full assessment and characterization of diffuse inflammatory myopathy. 38
27708860 2016
28
Why do patients with myositis die? A retrospective analysis of a single-centre cohort. 38
27494511 2016
29
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. 38
27028907 2016
30
Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined by a novel chemiluminescent immunoassay. 38
27252266 2016
31
Inflammatory myopathies and overlap syndromes: Update on histological and serological profile. 38
27107515 2015
32
Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. 38
26198592 2015
33
Mosaic Tetrasomy 9p: A Mendelian Condition Associated With Pediatric-Onset Overlap Myositis. 38
26216333 2015
34
Idiopathic inflammatory myopathies and the lung. 38
26028634 2015
35
Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. 38
25673126 2015
36
Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. 38
25500701 2014
37
Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. 38
25183232 2014
38
[Therapeutic strategy in inflammatory myopathies (polymyositis, dermatomyositis, overlap myositis, and immune-mediated necrotizing myopathy)]. 38
24144868 2014
39
Idiopathic inflammatory myopathies. 38
24365315 2014
40
[Pathological features of myositis with myositis -specific autoantibodies]. 38
25672723 2014
41
Camptocormia as a clinical manifestation of polymyositis/systemic sclerosis overlap myositis associated with anti-Ku. 38
22453528 2013
42
The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. 38
23877355 2013
43
Classification, diagnosis, and management of idiopathic inflammatory myopathies. 38
23504386 2013
44
Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. 38
23269233 2013
45
Review: immune-mediated necrotizing myopathies--a heterogeneous group of diseases with specific myopathological features. 38
22989019 2012
46
Cardiac involvement in juvenile overlap-myositis detected by cardiac magnetic resonance imaging. 38
20971516 2011
47
Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. 38
21572147 2011
48
Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases. 38
21723454 2011
49
Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. 38
21376512 2011
50
Anti-PL7 antisynthetase syndrome under interferon therapy. 38
20851661 2011

Variations for Overlap Myositis

Expression for Overlap Myositis

Search GEO for disease gene expression data for Overlap Myositis.

Pathways for Overlap Myositis

GO Terms for Overlap Myositis

Sources for Overlap Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....